Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY, UK.
Pharmaceutical Technology & Development, AstraZeneca, Macclesfield, UK.
AAPS J. 2020 Feb 11;22(2):46. doi: 10.1208/s12248-019-0406-y.
The presence of different excipient types/brands in solid oral dosage forms may affect product performance and drug bioavailability. Understanding the biopharmaceutical implications of superdisintegrant variability (changes in material properties), variation (changes in excipient amount) and interchangeability (use of different excipient types with the same intended functionality) in oral drug performance would be beneficial for the development of robust final dosage forms. The current study investigated the impact of superdisintegrants (sodium starch glycolate, croscarmellose sodium, crospovidone) on the apparent solubility of drugs with different physicochemical properties (drug ionisation, drug lipophilicity, drug aqueous solubility). Compendial and biorelevant media were used to assess the impact of gastrointestinal conditions on the effects of excipient on drug apparent solubility. For the majority of compounds, changes in drug apparent solubility were not observed in superdisintegrant presence, apart from the cases of highly ionised compounds (significant decrease in drug solubility) and/or compounds that aggregate/precipitate in solution (significant increase in drug solubility). Excipient variability did not greatly affect the impact of excipients on drug apparent solubility. The use of multivariate data analysis identified the biopharmaceutical factors affecting excipient performance. The construction of roadmaps revealed that superdisintegrants may be of low risk for the impact of excipients on oral drug performance based on drug solubility alone; superdisintegrants activity could still be a risk for oral bioavailability due to their effects on tablet disintegration.
不同辅料类型/品牌在固体制剂中的存在可能会影响产品性能和药物生物利用度。了解超崩解剂变异(材料特性变化)、变异(辅料用量变化)和可互换性(使用具有相同预期功能的不同辅料类型)对口服药物性能的生物制药影响,将有助于开发稳健的最终剂型。本研究考察了超崩解剂(交联羧甲基淀粉钠、交联聚维酮、羧甲基淀粉钠)对具有不同理化性质的药物(药物离解度、药物亲脂性、药物水溶解度)表观溶解度的影响。采用法定和生物相关介质评估胃肠道条件对辅料影响药物表观溶解度的影响。对于大多数化合物,除了高度离解化合物(药物溶解度显著降低)和/或在溶液中聚集/沉淀的化合物(药物溶解度显著增加)外,在超崩解剂存在下,药物表观溶解度没有变化。辅料的变异并没有很大地影响辅料对药物表观溶解度的影响。多元数据分析用于确定影响辅料性能的生物制药因素。路线图的构建表明,基于药物溶解度,超崩解剂对口服药物性能的影响风险可能较低;但由于超崩解剂对片剂崩解的影响,其对口服生物利用度仍可能存在风险。